


# Dermatologic Events Associated With the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

Amy C.M. Musiek, Kerri E. Rieger, Martine Bagot, Jennifer N. Choi, David C. Fisher, Joan Guitart, Paul L. Haun, Steven M. Horwitz, Auris Onn-Lay Huen, Bernice Y. Kwong, Mario E. Lacouture, Sarah J. Noor, Alain H. Rook, Lucia Seminario-Vidal, Maarten H. Vermeer, Youn H. Kim. *Dermatology and Therapy* (2021).

## Recommended Management of Mogamulizumab-Associated Rash in MF/SS



BSA, body surface area; GABA, gamma-aminobutyric acid; moga, mogamulizumab; MF/SS, mycosis fungoides/Sézary syndrome.

<sup>1</sup>National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. National Cancer Institute website. 2018.